



0040000018

The
Patent
Office

0300/144

PCT/GB 00/00144



INVESTOR IN PEOPLE

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

The Patent Office

Concept House

Cardiff Road

Newport RECD 28 JUN 2000

South Wales

NP10 8QQ PO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Charles George

Dated 25 MAY 2000



Patents Form 1/77

5 A 77
(16)



17FEB99 E426053-1 D00354
P01/7700 0.00 - 9903561.0

Request for grant of a patent
(see the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help
you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	PBA/D088342PGB		
2. Patent application number (The Patent Office will fill in this part)	9903561.0 17 FEB 1999		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	ADVANCED MEDICAL SOLUTIONS LIMITED ROAD THREE WINSFORD INDUSTRIAL ESTATE WINSFORD CHESHIRE CW7 3PD UNITED KINGDOM 758790000 1		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of its incorporation			
4. Title of the invention	CELL GROWTH		
5. Name of your agent (if you have one)	Marks & Clerk		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Sussex House 83-85 Mosley Street Manchester M2 3LG		
Patents ADP number (if you know it)	18004		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day/month/year)
8. Is a statement of Inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 14

Claim(s) 6

Abstract -

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of Inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(Please specify) -

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

MARKS & CLERK

17/02/99

12. Name and daytime telephone number of person to contact in the United Kingdom

MR. P. B. ATKINSON - 0161 236 2275

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay, please contact the Patent Office.

CELL GROWTH

The present invention relates to substrates for use in cell growth and to methods of producing such substrates. The invention relates more particularly to substrates having cell adhesion promoting activity which may be used in various cell growth applications, e.g. wound healing and tissue engineering. The invention also relates to methods of preparing such substrates and their use in various cell growth applications.

All eukaryotic, mammalian cells are substrate dependent in that they need to be attached to a surface in order to be able to grow, or secrete or divide. The phenotype that cells express is partly determined by their interaction with the substrate to which they are attached. The substrate to which mammalian cells are attached is collagen. All body soft (excluding blood) and hard tissues are made up of cells attached to a framework of collagen. Collagen is a protein that forms fibres and the fibres form matrices, these matrices may form any configuration from random to aligned.

The collagen fibres are themselves made up of fibrils so a collagen fibre resembles a cable of aligned fibrils. The chemistry of the collagen fibril varies according to the tissue type and a range of collagens have been identified.

Substrates for tissue augmentation or to act as carriers for cultured cell transfer in wound therapy are usually collagen based. In this situation, the collagen substrate usually has to be specific to the type of cell growth required and the phenotype and status (secretory, replicatory) grown on the substrate may not turn out to be as required.

US-A-5 610 148 (R.Brown) entitled "Macroscopically Orientated Cell Adhesion Protein" describes the production of a fibre comprised of fibrils of a cell adhesion protein selected from fibronectin (Fn), vitronectin and von Willebrand protein that has been denatured and the polymer chains then aligned by unidirectional

shear allowing aggregation and precipitation. These fibres are of a fibular construction not dissimilar in some respects to collagen. Cells seeded onto the fibres demonstrate directional cell growth as a result of the longitudinal orientation of the cell adhesion binding site. However such fibre structures require a high concentration of fibronectin or fibrinogen/fibronectin, are somewhat complicated to produce and are of relatively low strength.

It is an object of the present invention to obviate or mitigate the above mentioned disadvantages.

According to the present invention there is provided a substrate for cell growth comprising a polysaccharide basal layer having a surface layer of a cell adhesion protein.

Substrates in accordance with the invention have the advantage (over substrates comprised of fibrils of fibronectin or other cell adhesion protein) of being of higher strength than a substrate comprised substantially of 100% protein and are also easier to manufacture. The substrates of the invention may be used in a wide range of cell growth applications, e.g. wound repair, tissue repair or augmentation, or for the growth of cells in routine cell culture *in vitro*, in large scale cell culture, bioreactors or organ culture.

In the substrates of the invention, the orientation of the cell adhesion protein is not necessarily significant and guidance of the cells during growth thereof is achieved by the physical form of the substrate. Thus, for example, in the case of a fibre (see below) cell growth may occur along and/or around the fibre as determined by the presence of the cell adhesion protein. We do not however preclude the possibility of the cell adhesion protein having at least some degree of alignment.

The polysaccharide basal layer will for preference have a thickness of at least 60%, more preferably at least 80% and ideally at least 90% of the combined depth of the basal layer and cell adhesion protein layer.

The cell adhesion protein provided as a surface layer for the polysaccharide basal layer may be an integral layer or may be a surface absorbed molecular layer. The surface layer of the cell adhesion protein may, depending on the method by which it is produced, be only several molecules thick or may be of somewhat greater thickness so as to form a discrete outer layer. Thus, the protein layer may be anything from 3-5 molecules "deep" in the case of surface adsorption to, say, 20 μ m (e.g. 1-20 μ m) when formed as a "coating". This protein layer may be essentially amorphous network, have some crystallinity or even little or no fibril structure. The protein layer may be stabilised and attached to the basal (polysaccharide) layer to different degrees by different physical and/or chemical mechanisms. Examples of such attachment and stabilisation including covalent bonding, hydrogen bonding, van der Waals forces and physical entrapment. In the case where the polysaccharide incorporate carboxylic groups, covalent attachment may be achieved by a carbodiimide which "couples" a carboxylic group of the polysaccharide with an amino group of a protein. A further possibility is the use of a melamine-formaldehyde resin. The degree of stability of the protein layer can be used as a mechanism to drive certain cell responses. Thus the substrate may be "tailored" to ensure growth of a particular cell type and/or to provide a known degree of cell growth in a predetermined time.

Substrates in accordance with the invention may be produced by a number of methods. In one such method, a solution containing dissolved polysaccharide and cell adhesion protein (the solution containing less of the protein than the polysaccharide) is extruded into a coagulation bath such that a substrate comprised of a basal layer of polysaccharide and a surface layer of cell adhesion protein is precipitated. The coagulation bath may incorporate, for example, di- or higher- valent cations (e.g. Ca^{2+}) which serve to effect the precipitation and also stabilise the protein layer by ion bridging. In an alternative method of producing the substrate, a surface layer of a cell adhesion protein may be applied to a preformed polysaccharide. Application of the protein layer may be effected, for example, in a coating bath containing a solution of protein or by a technique such as spraying. Stabilisation of the surface layer may be by a carbodiimide.

The cell adhesion protein preferably incorporates the RGD (Arginine, Glycine, Aspartic acid) binding site. It is particularly preferred that the cell adhesion protein is fibronectin, vitronectin or von Willebrand protein or a fragment of such proteins incorporating this RGD binding site.

The preferred cell adhesion protein is fibronectin which may be used in the form routinely isolated from blood plasma, e.g. by cryoprecipitation. The fibronectin may contain fibrinogen and albumin.

The polysaccharide layer will for preference comprise at least 50%, more preferably at least 60%, even more preferably at least 80% and ideally at least 90% polysaccharide. The cell adhesion protein layer will preferably comprise at least 50%, more preferably at least 60% even more preferably at least 80% and ideally at least 90% of cell adhesion protein.

The cell adhesion protein layer may incorporate proteins other than cell adhesion proteins.

Cell growth substrates in accordance with the invention may incorporate, in the polysaccharide layer, an active agent for delivery during the cell growth application. This agent may, for example, be deliverable by diffusion and might for example be a drug. Further examples of active agents include growth factors, chemotactic agents etc. The active agents may be free or encapsulated, for example in lipid type droplets. The active agent may be disposed continuously or discontinuously along, across and/or around the cell growth substrate and may be provided in different amounts at different regions of the substrate so as to establish a concentration gradient.

Examples of polysaccharides which may be used for the basal layer of the cell growth substrate include alginates, chitosan, polylysine and other polyamino acids, cationic starches, cationic derivatives of other hydrocolloids, collagen, gelatine, low-methoxyl pectin, carrageenans, polyacrylic acids (e.g. Carbopol), chondroitin

sulphate, hyaluronic acid, carboxymethyl cellulose, carboxymethyl starch, carboxymethyl guar, cellulose sulphate, dextron sulphate, gellan, xanthan, and anionic derivatives of other hydrocolloids. We particularly prefer that the polysaccharide base layer is comprised of an alginate material cross-linked with calcium ions as other di- or higher valent cation capable of cross-linking alginates.

Particularly preferred examples of cell growth substrates in accordance with the invention are in the form of fibres having a core (providing the basal layer) which consists of, or is rich in, the polysaccharide material and a surface at which the cell adhesion protein is provided.

Fibres in accordance with the invention may have a diameter of 10-1000 μ m, more preferably 40-150 μ m, even more preferably 40-100 μ m, and ideally 50-80 μ m. the fibres may be of any appropriate length.

Such fibres may be produced by spinning a dope comprised of a solution of the polysaccharide into a coagulation bath causing precipitation of the fibres. The dope may also contain dissolved cell adhesion protein which is to form the surface layer with the spinning technique being such that there is preferential initial precipitation of polysaccharide in the coagulation bath followed by later precipitation of the cell adhesion protein which thus forms a protein rich outer layer of the fibre (this layer being integral with the core). The dope for use in this process may for example comprise (based on the total weight of the polysaccharide and cell adhesion protein) 60-95% (preferably about 90%) by weight of the polysaccharide and 5-40% (preferably about 10%) by weight of the cell adhesion protein. The fibre produced by such a process may have a core comprised of 50-80% by weight of the polysaccharide and an outer layer comprised of 50-80% by weight of the cell adhesion protein and 20-50% by weight of the polysaccharide.

In an alternative spinning method, fibres may be formed by a co-axial extrusion technique in which a solution of the cell adhesion protein is extruded co-axially around a (separate) solution of the polysaccharide, both solutions being spun

into the same coagulation bath, whereby a fibre having a polysaccharide core and a surface layer of the cell adhesion protein is formed.

In an alternative process of producing the fibres, a dope comprised of a solution of the polysaccharide (but not the cell adhesion protein) may be spun into a coagulation bath and the fibre thus formed is treated with the cell adhesion protein. This treatment may be effected, for example, by providing the cell adhesion protein in the coagulation bath so that the protein is adsorbed as a surface layer onto the basal polysaccharide layer. It is however more preferred that the cell adhesion protein is applied in a bath downstream of the coagulation bath. The conditions in the protein bath may be such as to ensure formation of a stabilised coating of the protein layer is obtained.

Furthermore, for all embodiments of fibre formation, the cell adhesion protein should be concentrated at the fibre surface. If the fibre is produced by co-spinning a solution of the polysaccharide and cell adhesion protein the combination of relative molecular size, hydrophilic/hydrophobic balance and relative stability can be used to cause preferential precipitation. If the fibre is produced by a two-stage process then concentration of the protein at the surface may be achieved by the use of concentration of the polysaccharide and protein at each stage, first stage mixed polysaccharide and protein, second stage predominantly protein plus surface active agents and/or stabilisers.

Whichever method is used, the protein should be stabilised at the surface and, in fact, the lower the amount of protein the more important the stabilisation becomes. Stabilisation may be effected by ensuring that parts of the molecular chain of the protein are embedded in the bulk polysaccharide. In the case where the polysaccharide has been cross-linked by divalent cations, stabilisation of the protein may be by divalent cation bridges. When chitosan is used to form the core, carrier cation bridging will only occur within the protein species which will help to stabilise the protein at the surface.

More specific embodiments of producing fibres in accordance with the invention are described below.

In one such embodiment, a fibre is produced by ejecting an aqueous solution of sodium alginate through a spinneret into a coagulation bath containing Ca^{2+} ions. The fibre is then passed through a fibronectin solution (or mixed protein solution) in a coating bath (downstream of the coagulation bath) which is at a pH that will give fibronectin a net positive charge causing it to be capable of interacting with the alginic acid. The fibronectin can be further bound to the alginate by passing the fibre through a coagulation/stabilisation bath at a pH that favours fibronectin to become negatively charged thus favouring divalent cation bridging so as to stabilise the fibronectin on the polysaccharide. Alternatively, this bath may incorporate carbodiimide for effecting covalent bonding if the protein to the polysaccharide the coagulation/stabilisation bath may contain agents that modify either directly the interaction of the fibre with cells (for example through the nature of a counterion, e.g. Zn, Ag, Mn, Ce) or indirectly by influencing the surrounding environment by diffusion of an active molecular species, such as growth factors, aggregating agents, chemoattractants, surfactants, etc.

As an alternative to applying the fibronectin in a coating bath, it is possible to apply a fibronectin coating by spraying a fibronectin solution onto the fibre. Spraying provides. Spraying provides a means of thin coating (i.e. only several molecules thick) and also a method of coating that will potentially produce a fibrillar form of the coating if the conditions of shear etc. are set correctly. These conditions may also be adjusted to give orientation of the fibril formed in relation to the substrate.

In a further embodiment of fibre production, fibres may be found in a single stage process by spinning a dope containing dissolved sodium alginate and fibronectin into a solution of calcium ions (which provide the driving force for precipitation). The dope is formulated such that the fibronectin is preferentially precipitated at the surface of the fibre. The relative amounts of the calcium alginate to

the fibronectin in the dope would preferably be of the order of at least 80 parts by weight alginate and at most 20 parts fibronectin.

In the process described in the preceding paragraph, the fibre would be produced under conditions that encourage the globular nature of the protein. This may be achieved by use of a pH or temperature (for the coagulation bath) that causes chains of the protein molecule to "roll-up" on themselves with a tendency to embed the ends of the chain in the fibre structure.

In an alternative fibre production the process, a polyelectrolyte such as chitosan would be mixed with the fibronectin solution and a fibre precipitated by spinning into a sodium hydroxide bath. The molecular weight of the chitosan would be chosen to encourage fibre formation.

As an alternative to the process described in the previous paragraph it is possible to spin a dope comprising a solution of chitosan (as the polysaccharide) to form a fibre which may subsequently be coated with fibronectin. This coating (of fibronectin) would be formed by charge interaction directly between the charged chitosan side chains and the amino acid groups of the fibronectin as well as by cationic bridging.

Further methods of producing fibres comprised of a polysaccharide core and a surface layer of a cell adhesion protein are disclosed in our co-pending application entitled "Fibres" filed concurrently herewith, the disclosure of which is incorporated by reference.

For all methods of fibre production, it may be appropriate to subject the spun fibres to stretching, washing, and/or drying operations. In the case where a (separate) surface treatment of the cell adhesion protein is applied after formation of the basal polysaccharide layer, it may be appropriate to effect stretching and/or washing prior to the treatment with the cell adhesion protein.

Whilst fibres are the preferred form of the cell growth substrate in accordance with the invention, other forms are possible. Examples include sheets and strips which may be produced by forming (by a knife over roll or transfer coat or slot dye method) a thin film of a solution of the polysaccharide which is then precipitated in a coagulation bath. As in the case of fibre formation, the solution may also incorporate the cell adhesion protein to be preferentially deposited on coagulation at the surface of the polysaccharide. Alternatively the solution to be precipitated in the coagulation bath need not include the cell adhesion protein which may then be applied subsequently to the sheet or strip by spraying with a solution of the protein. In this case, the nature of the coating is determined by the concentration of the protein in solution, the velocity, orifice, size and direction of spray relative to the surface. Judicious adjustment of these parameters should produce undenatured but aligned molecules of active protein. The surface layer of the cell adhesion protein may be applied to the sheet by spraying with a solution of the protein. By spraying at high concentration and flow rate through a small orifice, protein denaturation, fibril formation and alignment can be obtained and if this is directed in parallel to a surface then this alignment will be maintained in the surface coat obtained molecular alignment of the protein will then be reflected in the alignment of cellular species grown on the substrate.

Irrespective of the physical form (fibre, sheet etc) of the cell growth substrate of the invention and also irrespective of the manner in which the cell adhesion protein surface layer is incorporated therein, it is preferred that basal polysaccharide layer is formed by a spinning or extruding a solution of sodium alginate into a bath containing calcium ions. Preferred sodium alginate for use in such a technique have a Guluronic acid (G) content of at least 35% by weight and a Mannuronic acid (M) content of at most 65% by weight. Preferably the G-content is 35-70% by weight and the M-content is 65-30% by weight. M preferably also the sodium alginate has a viscosity for a 1% solution (in water) of the sodium alginate of 30-300 cP, more preferably 40-100 cP. The alginate solution to be spun or extruded into the coagulation bath should generally have a total dissolved solids content of less than 10% by weight, more preferably in the range 5-7%. The amount of the cation (e.g. calcium) present in the

coagulation bath (to effect precipitation of the alginate) is preferably less than 1% by weight.

For products in accordance with the invention produced by coagulation of a solution of an alginate, it is possible for the alginate solution (to be coagulated) to contain at least one additional polysaccharide to modify the properties of the alginate. The additional polysaccharide may, for example, be one having COO^- groups along the polysaccharide chains, for example pectin, carboxymethyl cellulose N-, O-carboxymethyl chitosan, carrageenan, xanthan or gellan. Alternatively or additionally the polysaccharide to the coagulated with the alginate may be one having SO_4^{2-} groups provided along the polysaccharide chain, e.g. chondroitin sulphate, dermatan sulphate, heparan sulphate or heparan. Uncharged polysaccharides may be used in conjunction with the alginate, e.g. acemannan. The additional polysaccharide may be one which improves the water absorbency of the alginate. Further disclosure of products obtained by coagulation of an alginate solution containing at least one other polysaccharide are given in WO-A-9610106 (Innovative Technologies Ltd), the disclosure of which is incorporated herein by reference.

For all cell growth substrates in accordance with the invention, the surface layer of the cell adhesion protein may be continuous or discontinuous. Thus, for example, in the case of a fibre, the protein may be provided continuously along and around the fibre length or as periodic repeats (e.g. of predetermined length) along the fibre length and at least partially around the circumference of the fibre, or as "stripe" which does not extend completely around the circumference and which extends continuously or discontinuously along the fibre length. If the cell adhesion protein layer is discontinuous, parts of the surface of the cell growth substrate may (when used for cell growth) be positively interactive ("talking") and other parts passive ("silent") and other parts negatively interactive ("discouraging"). In cellular terms, this means that a positive surface encourages cell adhesion spreading, motility and growth whereas a passive surface ("silent") may have a low level of interaction.

Cell growth substrates in accordance with the invention may, if desired, have a channel or groove formation for the purpose of providing guided cell growth (along

the multidudinal direction of the channel). This formation may be an open-topped channel or groove. Typically the groove or channel will have a width of 5-50 μ m (more preferably 5-30 μ m) and a depth of 3-50 μ m (more preferably 3-30 μ m). The channel or groove may be of any desired configuration, e.g. U-, "rectangular" or "square"-U or V-shaped. In the case of a fibre, the groove or channel formation may extend parallel to the fibre axis but other configurations are possible, e.g. helical. More than one groove or channel may be provided along the length of the fibre. In case of a cell growth substrate in accordance with the invention in the form of a film or sheet, a plurality of parallel grooves or channels may be provided along the surface of the substrate. These grooves or channels may be formed as corrugations.

Cell growth substrates in accordance with the invention may be used in a number of forms for various cell growth applications. Purely by way of example, substrates in the form of fibres may be formed into a structure, e.g. random matrices (e.g. non-woven felts and fleeces), orientated matrices (fibres having some relative alignment), knitted structures (e.g. knitted cloths), braided structures (e.g. braided thread), bundled structures, and carded slivers. One preferred structure comprises fibres in accordance with invention laid in parallel to each other and for preference bonded to a supporting layer, e.g. a polyurethane film. This supporting layer may be adhesively coated.

A further possibility relates to fibres produced with a polysaccharide (e.g. alginate) cross-linked by a di- or higher-valent cation (e.g. calcium). Such fibres may (using the techniques disclosed in WO-A-9613285 (Innovative Technologies Ltd) be admixed with an aqueous solution of a hydrogel precursor material whereby the cations from the fibres cross-link the precursor material resulting in the formation of a hydrogel in which the molecules of the hydrogel precursor are cross-linked by the di- or higher-valent cations donated by the fibres. The admixture may incorporate a plasticiser. Subsequently water may be removed from the hydrogel so as to provide a dehydrated form thereof containing the fibres as reinforcement. Such a product is eminently suitable for use on wound healing during which fibres will become exposed

at the surface of the product to provide a substrate for cell growth. The hydrogel precursor may for example be sodium alginate and the plasticiser may for example be glycerol, polyethylene glycol, sorbitol or a PEO/PPO polymer.

Cell growth substrates in the form of strips or sheets may for example be rolled into tubes or other three dimensional structures.

As indicated above, cell growth substrates in accordance with the invention may be used in a range of cell growth applications. If cell alignment on the surface of the substrate is important then this may be imposed by the nature of the cell and its relationship to its surface. For example, cell alignment may be determined by the size of a fibre on which the cell is grown or by the dimensions of a groove or channel on the substrate for guiding the cell. Alternatively, tracts on the substrate surface provided with the cell adhesion protein and some tracts without the protein. If cell-long alignment either across or parallel to a particular axis of the substrate is required then this can be accomplished by either exposure of the surface to flow which will produce a wall shear stress parallel to the desired orientation or to axial strain which would tend to cause the cells to lie across the axis of stress and therefore across the axis of the surface.

A number of specific (but non-limiting) examples of uses of cell growth substrates in accordance with the invention will now be given.

Wound Therapy

The substrates may be used in wound therapy. For this purpose, a cell-growth substrate (in accordance with the invention) in the form of a flat sheet or film may be preferred. The sheet or film may have a surface grooving or corrugation to direct the orientation of cell growth. The film or sheet material may incorporate an agent to be delivered to the wound.

Alternatively, parallel arrays of fibres with or without seeded cells may be placed on the wound either individually, in a bundled or fixed to a support which may be adhesively coated. An example of a suitable support is polymeric film material

particularly a breathable film (e.g. high MVTR film). The film may be one having an MVTR when in contact with liquid water which is at least twice that when in contact with moisture vapour (but not liquid water). For example, the MVTR in contact with water vapour only may be $3000-5000 \text{ g m}^{-2} 24\text{hr}^{-1}$ (as measured by ASTM E96B) and an MVTR in the presence of liquid water (as measured by ASTM E96BW) of 8000 to $10000 \text{ g m}^{-2} 24\text{hr}^{-1}$. The support may have apparatus to allow exudate transfer. Whether or not a support is used, the fibres applied to the wound may incorporate growth factors for delivery to surface cells or incorporate agents that will influence the surrounding environment, e.g. bactericides etc. Mixtures of fibres may be applied to the wound, e.g. any two of (i) fibres seeded with cells, (ii) unseeded fibres, and (iii) fibres containing an agent to be delivered to the wound.

Cultured Epidermal and Dermal Substitutes

Cell growth substrates in accordance with the invention may be cultured with single layers of epidermal keratinocytes or dermal fibroblasts (either of which may be of autologous or heterologous origin.) The substrate (with cultured cells) may be used alone or in combination with similarly cultured substrates. These substrates and cells may be used for the treatment of partial thickness wounds, e.g. donor sites and for treatment of ulcers.

Tissue Augmentation/Repair

Cell growth substrates in the form of continuous fibres can be positioned in relation to a damaged organ or structure. They may be placed either singularly or in bundles during invasive or non-invasive therapy.

Alternatively, cell growth substrates in the form of fibres may be provided as an injectable suspension. The suspension may be introduced into the body along a catheter guide system or the fibres may be formed at the site. As an alternative, it is possible to formulate to solution one containing the polysaccharide, the other coagulant therefore with at least one of the solutions containing cell adhesion protein and to apply these solutions to a patient under conditions such that fibre formation occurs *in situ*, the fibre formed possibly being continuous.

Orthopaedic

Cell growth substrates in the form of fibres may be aligned parallel to tendons and seeded *in situ* with appropriate cells, chondrocytes, etc. Alternatively, fibres plus cell may be cultured in a laboratory and then delivered to the patient. For both embodiments, the fibres may contain, or be associated with fibres constructed with hyaluronic acid or other cartilage-derived substances.

Vascular Graft

Cell growth substrates in the form of fibres may be knitted, woven or spun into tubes to encourage cell growth to form a blood conduit.

Nerve Regeneration

— Damaged nerves can be repaired using fibres to link the two (separated) ends of the nerve thus providing a path along which the new nerve can grow.

Drug delivery

Cell growth substrates may incorporate active molecules located in the polysaccharide layer. These agents may be used to influence the fibre incorporation into the tissue. Alternatively the agent may provide a drug reservoir for the purposes topical or systemic therapy.

Claims

1. A substrate for cell growth comprising a polysaccharide basal layer having a surface layer incorporating a cell adhesion protein.
2. A substrate as claimed in claim 1 wherein the polysaccharide basal layer has a thickness greater than 60% of the thickness of this layer and the polysaccharide basal layer.
3. A substrate as claimed in claim 2 wherein the polysaccharide basal layer has a thickness greater than 80% of the thickness of this layer and the polysaccharide basal layer.
4. A substrate as claimed in any one of claims 1 to 3 wherein the cell adhesion protein layer is integral with the polysaccharide basal layer.
5. A substrate as claimed in claim 4 wherein the layer of the cell adhesion protein has a thickness of 1-20 μ m.
6. A substrate as claimed in any one of claims 1 to 4 wherein the layer of the cell adhesion protein is a surface adsorbed layer.
7. A substrate as claimed in claim 5 wherein the layer of the cell adhesion protein is 3-5 molecules deep.
8. A substrate as claimed in any one of claims 1 to 7 wherein the polysaccharide basal layer comprises at least 80% by weight of polysaccharide.
9. A substrate as claimed in claim 8 wherein the polysaccharide basal layer comprises at least 90% by weight of polysaccharide.
10. A substrate as claimed in any one of claims 1 to 9 wherein the surface layer of the cell adhesion protein comprises at least 80% by weight of the cell adhesion protein.

11. A substrate as claimed in claim 10 wherein the surface layer of the cell adhesion protein comprises at least 90% by weight of cell adhesion protein.
12. A substrate as claimed in claim 11 wherein the surface layer of cell adhesion protein comprises 95 to 100% by weight of cell adhesion protein.
13. A substrate as claimed in any one of claim 1 to 12 wherein the polysaccharide is an alginate.
14. A substrate as claimed in claim 13 wherein the alginate has a Guluronic acid (G) content of at least 35% by weight and Mannuronic acid (M) content of at most 65% by weight.
15. A substrate as claimed in claim 14 wherein the polysaccharide has a G content of 35-70% by weight and an M content of 65-30% by weight.
16. A substrate as claimed in any one of claims 13 to 15 wherein the alginate is cross-linked with calcium ions.
17. A substrate as claimed in claim 16 wherein the cell adhesion protein is stabilised by calcium ion bridges.
18. A substrate as claimed in any one of claims 1 to 16 wherein the cell adhesion protein is stabilised by carbodiimide.
19. A substrate as claimed in any one of claims 1 to 18 wherein the cell adhesion protein incorporates the RGD binding site.
20. A substrate as claimed in claim 19 wherein the cell adhesion protein is fibronectin, vitronectin or von Willebrand protein.

21. A substrate as claimed in claim 20 wherein the cell adhesion protein is fibronectin.
22. A substrate as claimed in any one of claims 1 to 21 wherein the cell adhesion protein layer is discontinuous layer.
23. A substrate as claimed in any one of claims 1 to 22 wherein the polysaccharide layer incorporates an active agent.
24. A substrate as claimed in claim 23 wherein the active agent is encapsulated.
25. A substrate as claimed in claim 23 or 24 wherein the active agent is a drug, growth factor or chemotactic agent.
26. A substrate as claimed in any one of claims 1 to 25 having at least one groove or channel formation having a width of 5-50 μm and depth of 3-50 μm
27. A substrate as claimed in claim 26 wherein the channel formation has a width of 5-30 μm and a depth of 3-30 μm .
28. A substrate as claimed in any one of claims 1 to 27 in the form of a fibre.
29. A substrate as claimed in claim 28 wherein the fibre has a diameter of 10-1000 μm .
30. A substrate as claimed in claim 29 wherein the fibre has a diameter of 40-150 μm .
31. A substrate as claimed in claim 30 wherein the fibres has a diameter of 40-100 μm .
32. A substrate as claimed in claim 31 wherein the fibre has a diameter of 50-80 μm .

33. A substrate as claimed in any one of claims 1 to 27 which is in the form of a sheet or film.
34. A substrate as claimed in claim 33 having a thickness of 200-2000 μ m.
35. A substrate as claimed in claim 34 having a thickness of 10-100 μ m.
36. A substrate as claimed in claim 33 having a thickness of 200-1000 μ m
37. A substrate as claimed in claim 36 having a thickness of 500-2000 μ m.
38. An assembly of fibres as claimed in any one of claims 28 to 32.
39. An assembly as claimed in claim 38 in the form of a random matrix (e.g. a non-woven felt or fleece), orientated matrix (fibres having some relative alignment), a knitted structure, a braided structure, a bundled structure or a carded sliver.
40. An assembly comprising a plurality of fibres as claimed in any one of claims 28 or 32 wherein the fibres are arranged in parallel to each other.
41. An assembly as claimed in claim 40 wherein the parallel fibres are provided on a support in the form of a sheet or film.
42. An assembly as claimed in claim 41 wherein the fibres are provided on a high MVTR film.
43. A method of producing a cell growth substrate comprising extruding a solution containing dissolved polysaccharide and cell adhesion protein, the polysaccharide being present in an amount greater than the cell adhesion protein, into a coagulation bath such that a substrate comprised of a basal layer of a polysaccharide and a surface layer of cell adhesion protein is precipitated.

44. A method as claimed in claim 44 wherein the substrate is precipitated in a bath containing calcium ions.
45. A method as claimed in claim 43 or 44 wherein the solution to be extruded comprises (based on the total weight of the polysaccharide and cell adhesion protein) 60-95% by weight of the polysaccharide and 5-40% by weight of the cell adhesion protein.
46. A method as claimed in any one of claims 43 to 45 wherein the dissolved polysaccharide is sodium alginate.
47. A method as claimed in claim 46 wherein the sodium alginate has a G-content of 35-70% by weight and an M-content of 65-35% by weight.
48. A method as claimed in claim 46 or 47 wherein the sodium alginate has a viscosity for a 1% solution (in water) of 30-300 cP.
49. A method as claimed in claim 48 wherein the sodium alginate has a viscosity of a 1% solution (in water) of 40-100 cP.
50. A method of producing a cell growth substrate comprising applying to the surface of a preformed layer of a polysaccharide a surface layer of a cell adhesion protein.
51. A method as claimed in claim 50 wherein the method of application is by immersion of the polysaccharide layer in a coating bath containing the cell adhesion protein.
52. A method as claimed in claim 50 wherein the method of application is by spraying.

53. A method as claimed in any one of claims 50 to 52 effected with stabilisation of the cell adhesion protein layer.

54. A method as claimed in claim 53 wherein the stabilisation is effected with carbodiimide.

55. A method of cell culture comprising effecting growth of cells on a substrate as claimed in any one of claims 1 to 37 or an assembly as claimed in any one of claims 38 to 42.

56. A method as claimed in 55 wherein the cell growth is for wound repair, tissue repair or augmentation, culturing epidermal or dermal substitute, orthopaedic application, vascular grafts, nerve regeneration or cell culture in a bioreactor.

57. The use of a substrate as claimed in any one of claims 1 to 37 or an assembly as claimed in any one of claims 38 to 42 in therapy.

Kenosha
Fangs & Arches
1981